Logo image of HIVE

HIVE DIGITAL TECHNOLOGIES LT (HIVE) Stock Fundamental Analysis

USA - NASDAQ:HIVE - CA4339211035 - Common Stock

4.1 USD
+0.29 (+7.61%)
Last: 9/15/2025, 10:47:08 AM
Fundamental Rating

5

Taking everything into account, HIVE scores 5 out of 10 in our fundamental rating. HIVE was compared to 280 industry peers in the Software industry. HIVE scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. HIVE is not priced too expensively while it is growing strongly. Keep and eye on this one!


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year HIVE was profitable.
HIVE had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: HIVE reported negative net income in multiple years.
Each year in the past 5 years HIVE had a positive operating cash flow.
HIVE Yearly Net Income VS EBIT VS OCF VS FCFHIVE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100M -200M

1.2 Ratios

The Return On Assets of HIVE (4.57%) is better than 71.79% of its industry peers.
HIVE's Return On Equity of 5.13% is fine compared to the rest of the industry. HIVE outperforms 69.29% of its industry peers.
Industry RankSector Rank
ROA 4.57%
ROE 5.13%
ROIC N/A
ROA(3y)-37.49%
ROA(5y)-16.27%
ROE(3y)-49.77%
ROE(5y)-22%
ROIC(3y)N/A
ROIC(5y)N/A
HIVE Yearly ROA, ROE, ROICHIVE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200 -400 -600

1.3 Margins

With an excellent Profit Margin value of 22.36%, HIVE belongs to the best of the industry, outperforming 88.57% of the companies in the same industry.
The Operating Margin and Gross Margin are not available for HIVE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) 22.36%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
HIVE Yearly Profit, Operating, Gross MarginsHIVE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100 -200 -300 -400

More info and screens

6

2. Health

2.1 Basic Checks

HIVE does not have a ROIC to compare to the WACC, probably because it is not profitable.
HIVE has more shares outstanding than it did 1 year ago.
The number of shares outstanding for HIVE has been increased compared to 5 years ago.
The debt/assets ratio for HIVE has been reduced compared to a year ago.
HIVE Yearly Shares OutstandingHIVE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M
HIVE Yearly Total Debt VS Total AssetsHIVE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

2.2 Solvency

An Altman-Z score of 7.26 indicates that HIVE is not in any danger for bankruptcy at the moment.
HIVE's Altman-Z score of 7.26 is fine compared to the rest of the industry. HIVE outperforms 77.86% of its industry peers.
HIVE has a Debt/Equity ratio of 0.03. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.03, HIVE is in the better half of the industry, outperforming 60.36% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Altman-Z 7.26
ROIC/WACCN/A
WACC10.39%
HIVE Yearly LT Debt VS Equity VS FCFHIVE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M 300M 400M

2.3 Liquidity

HIVE has a Current Ratio of 3.42. This indicates that HIVE is financially healthy and has no problem in meeting its short term obligations.
HIVE has a Current ratio of 3.42. This is amongst the best in the industry. HIVE outperforms 80.71% of its industry peers.
A Quick Ratio of 3.42 indicates that HIVE has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 3.42, HIVE belongs to the best of the industry, outperforming 81.07% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.42
Quick Ratio 3.42
HIVE Yearly Current Assets VS Current LiabilitesHIVE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M

More info and screens

8

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 145.17% over the past year.
HIVE shows a small growth in Revenue. In the last year, the Revenue has grown by 4.47%.
The Revenue has been growing by 31.59% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)145.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%500%
Revenue 1Y (TTM)4.47%
Revenue growth 3Y-18.07%
Revenue growth 5Y31.59%
Sales Q2Q%41.47%

3.2 Future

HIVE is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 84.23% yearly.
The Revenue is expected to grow by 53.13% on average over the next years. This is a very strong growth
EPS Next Y1251.77%
EPS Next 2Y368.34%
EPS Next 3Y84.23%
EPS Next 5YN/A
Revenue Next Year187.08%
Revenue Next 2Y101.53%
Revenue Next 3Y53.13%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
HIVE Yearly Revenue VS EstimatesHIVE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 100M 200M 300M 400M
HIVE Yearly EPS VS EstimatesHIVE Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2021 2022 2023 2024 2025 2026 2027 2028 0 1 -1 -2

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 31.54 indicates a quite expensive valuation of HIVE.
HIVE's Price/Earnings ratio is a bit cheaper when compared to the industry. HIVE is cheaper than 66.43% of the companies in the same industry.
HIVE is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 27.30, which is the current average of the S&P500 Index.
With a Price/Forward Earnings ratio of 10.83, the valuation of HIVE can be described as very reasonable.
Based on the Price/Forward Earnings ratio, HIVE is valued cheaply inside the industry as 91.79% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.73, HIVE is valued rather cheaply.
Industry RankSector Rank
PE 31.54
Fwd PE 10.83
HIVE Price Earnings VS Forward Price EarningsHIVE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HIVE Per share dataHIVE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5 2

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as HIVE's earnings are expected to grow with 84.23% in the coming years.
PEG (NY)0.03
PEG (5Y)N/A
EPS Next 2Y368.34%
EPS Next 3Y84.23%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for HIVE!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HIVE DIGITAL TECHNOLOGIES LT

NASDAQ:HIVE (9/15/2025, 10:47:08 AM)

4.1

+0.29 (+7.61%)

Chartmill FA Rating
GICS IndustryGroupSoftware & Services
GICS IndustrySoftware
Earnings (Last)08-14 2025-08-14/amc
Earnings (Next)11-13 2025-11-13
Inst Owners17.39%
Inst Owner Change47.01%
Ins Owners0.28%
Ins Owner Change0%
Market Cap949.23M
Analysts80
Price Target4.51 (10%)
Short Float %4.52%
Short Ratio0.43
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)185.32%
Min EPS beat(2)100.9%
Max EPS beat(2)269.73%
EPS beat(4)4
Avg EPS beat(4)130.87%
Min EPS beat(4)43.42%
Max EPS beat(4)269.73%
EPS beat(8)7
Avg EPS beat(8)88.66%
EPS beat(12)9
Avg EPS beat(12)16.46%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)0.88%
Min Revenue beat(2)-1.52%
Max Revenue beat(2)3.29%
Revenue beat(4)2
Avg Revenue beat(4)-0.05%
Min Revenue beat(4)-8.08%
Max Revenue beat(4)6.13%
Revenue beat(8)5
Avg Revenue beat(8)3.67%
Revenue beat(12)9
Avg Revenue beat(12)18.5%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)4.81%
PT rev (3m)-13.28%
EPS NQ rev (1m)51.52%
EPS NQ rev (3m)-1101.2%
EPS NY rev (1m)712.41%
EPS NY rev (3m)712.41%
Revenue NQ rev (1m)9.41%
Revenue NQ rev (3m)20.7%
Revenue NY rev (1m)9.62%
Revenue NY rev (3m)8.6%
Valuation
Industry RankSector Rank
PE 31.54
Fwd PE 10.83
P/S 7.38
P/FCF N/A
P/OCF 31.11
P/B 1.69
P/tB 1.69
EV/EBITDA N/A
EPS(TTM)0.13
EY3.17%
EPS(NY)0.38
Fwd EY9.24%
FCF(TTM)-0.52
FCFYN/A
OCF(TTM)0.13
OCFY3.21%
SpS0.56
BVpS2.42
TBVpS2.42
PEG (NY)0.03
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 4.57%
ROE 5.13%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 22.36%
GM N/A
FCFM N/A
ROA(3y)-37.49%
ROA(5y)-16.27%
ROE(3y)-49.77%
ROE(5y)-22%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.2
Health
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 206.22%
Cap/Sales 116.51%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.42
Quick Ratio 3.42
Altman-Z 7.26
F-Score5
WACC10.39%
ROIC/WACCN/A
Cap/Depr(3y)97.27%
Cap/Depr(5y)157.57%
Cap/Sales(3y)54.64%
Cap/Sales(5y)58.11%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)145.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%500%
EPS Next Y1251.77%
EPS Next 2Y368.34%
EPS Next 3Y84.23%
EPS Next 5YN/A
Revenue 1Y (TTM)4.47%
Revenue growth 3Y-18.07%
Revenue growth 5Y31.59%
Sales Q2Q%41.47%
Revenue Next Year187.08%
Revenue Next 2Y101.53%
Revenue Next 3Y53.13%
Revenue Next 5YN/A
EBIT growth 1Y-98.15%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year280.42%
EBIT Next 3Y69.4%
EBIT Next 5YN/A
FCF growth 1Y-313.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-33.66%
OCF growth 3Y-36.92%
OCF growth 5Y84.91%